TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸ASND

Ascendis Pharma A/S - Ordinary Share

NASDAQ
$274.50
▲ $57.90 (+26.7%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $274.89L $188.08+31.1%
$274.89$257.53$240.17$222.8$205.44$188.08$274.5
RSI (14)
Intraday · 15-minStrong buy+45RSI 68UptrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong buy+45
RSI (14)76
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$203.80
Resistance
$274.89
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
-10.7%
Buy & hold
+43.3%
Trades
11
Win rate
27%

$100,000.00 invested would be worth $89,277.11 (-10.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Ascendis Pharma A/S· Biotechnology

source: yahoo

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Sector
Healthcare
Industry
Biotechnology
Employees
1,189
Headquarters
Hellerup, Denmark
ascendispharma.com ↗

Fundamentals

source: yahoo
Market cap
$18.01B
P/E
31.8
P/B
30.6
EPS
$8.62
Div yield
—
Profit margin
57.3%
ROE
332.7%
Debt / Equity
1.84
Beta
—
52-week range
$160.86 – $274.89
52-week low · $160.86100% of rangehigh · $274.89

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:— Neutral0↑ · 0↓ · 8–
  • Ascendis Pharma Says Phase 3 Data Show TransCon CNP Improved Leg Alignment in Children With Achondroplasia— Neutral
    MT Newswires · 30 Jun 2026
  • Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial— Neutral
    GlobeNewswire · 30 Jun 2026
  • Ascendis Pharma Added to Multiple Russell Indexes— Neutral
    MT Newswires · 26 Jun 2026
  • RSI is 76 — overbought, which some traders treat as extended.
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
    — Neutral
    GlobeNewswire · 26 Jun 2026
  • Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?— Neutral
    Zacks · 26 Jun 2026
  • Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026— Neutral
    GlobeNewswire · 25 Jun 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.